Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Operating Expenses (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Operating Expenses for 4 consecutive years, with $4.7 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 8.23% to $4.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.7 million through Dec 2025, down 8.63% year-over-year, with the annual reading at $16.7 million for FY2025, 8.63% down from the prior year.
  • Operating Expenses for Q4 2025 was $4.7 million at bioAffinity Technologies, up from $3.7 million in the prior quarter.
  • The five-year high for Operating Expenses was $5.2 million in Q4 2024, with the low at $685279.0 in Q2 2022.
  • Average Operating Expenses over 4 years is $3.1 million, with a median of $3.8 million recorded in 2025.
  • The sharpest move saw Operating Expenses surged 180.12% in 2023, then dropped 15.62% in 2025.
  • Over 4 years, Operating Expenses stood at $1.6 million in 2022, then soared by 180.12% to $4.6 million in 2023, then increased by 13.13% to $5.2 million in 2024, then dropped by 8.23% to $4.7 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $4.7 million, $3.7 million, and $3.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.